Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000025.xml
Download PDF
CC BY-NC-ND 4.0 · Horm Metab Res 2022; 54(10): 677-685
DOI: 10.1055/a-1909-1922
DOI: 10.1055/a-1909-1922
Original Article: Endocrine Care
Association Of Blood Lipocalin-2 Levels with Gestational Diabetes Mellitus: A Systematic Review and Meta-Analysis
Funding This study was funded by Changzhou Health Commission Young Talents Project (QN202018), Natural Science Foundation of China (81900768), and General Project of Maternal and Child Health Research Project of Jiangsu Province (F201803).
Abstract
Lipocalin-2 (LCN2) is becoming recognized as a pleiotropic mediator of metabolic disorders. However, the relationship between LCN2 and gestational diabetes mellitus (GDM) is not well understood. We performed a systematic review and meta-analysis to explore it. A systematic search of Cochrane Library, PubMed, Embase, Scopus, Web of Science, Chinese National Knowledge Infrastructure, and Wan-fang Database was done for relevant articles published up to September 29, 2021. Standardized mean difference (SMD) with 95% confidence intervals (CI) was calculated to explore the association of LCN2 levels with GDM using Revman 5.3 and Stata 15.1. Fifteen case-control studies were included in this meta-analysis. The patients with GDM had significantly higher levels of blood LCN2 than parturients with normal glucose tolerance (SMD=3.41, 95% CI=2.24 to 4.58). Meta-regression and subgroup analysis were conducted to investigate the source of heterogeneity. Likely sources of heterogeneity were age and testing methods. This study found that GDM showed higher blood LCN2 levels than controls. However, caution is warranted on the interpretation of these findings. Standardized LCN2 measurement methods and longitudinal studies are required to disentangle and better understand the relationships observed.
Key words
lipocalin-2 - gestational diabetes mellitus - meta-analysis - insulin resistance - adipokinesPublication History
Received: 26 January 2022
Accepted after revision: 18 July 2022
Article published online:
07 October 2022
© 2022. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
References
- 1
Metzger BE,
Gabbe SG,
Persson B.
et al. International association of diabetes and pregnancy study groups recommendations
on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care 2010;
33: 676-682
MissingFormLabel
- 2 Ferrara A. Increasing prevalence of gestational diabetes mellitus: a public health perspective. Diabetes Care 2007; 30: S141-S146
- 3 Rodrigo N, Glastras SJ. The emerging role of biomarkers in the diagnosis of gestational diabetes mellitus. J Clin Med 2018; 7: 120
- 4 Yin X, Huo Y, Liu L. et al. Serum levels and placental expression of NGAL in gestational diabetes mellitus. Int J Endocrinol 2020; 8760563
- 5 McIntyre HD, Catalano P, Zhang C. et al. Gestational diabetes mellitus. Nat Rev Dis Primers 2019; 5: 47
- 6 Nguyen-Ngo C, Jayabalan N, Salomon C. et al. Molecular pathways disrupted by gestational diabetes mellitus. J Mol Endocrinol 2019; 63: R51-R72
- 7 de Gennaro G, Palla G, Battini L. et al. The role of adipokines in the pathogenesis of gestational diabetes mellitus. Gynecol Endocrinol 2019; 35: 737-751
- 8 Gutaj P, Sibiak R, Jankowski M. et al. The role of the adipokines in the most common gestational complications. Int J Mol Sci 2020; 21: 9408
- 9 Bhusal A, Rahman MH, Lee WH. et al. Paradoxical role of lipocalin-2 in metabolic disorders and neurological complications. Biochem Pharmacol 2019; 169: 113626
- 10 Xiao X, Yeoh BS, Vijay-Kumar M. Lipocalin 2: an emerging player in iron homeostasis and inflammation. Annu Rev Nutr 2017; 37: 103-130
- 11 Kjeldsen L, Bainton DF, Sengeløv H. et al. Identification of neutrophil gelatinase-associated lipocalin as a novel matrix protein of specific granules in human neutrophils. Blood 1994; 83: 799-807
- 12 Lou Y, Wu C, Wu M. et al. The changes of neutrophil gelatinase-associated lipocalin in plasma and its expression in adipose tissue in pregnant women with gestational diabetes. Diabetes Res Clin Pract 2014; 104: 136-142
- 13 Bhusal A, Lee WH, Suk K. Lipocalin-2 in diabetic complications of the nervous system: physiology, pathology, and beyond. Front Physiol 2021; 12: 638112
- 14 Cesur S, Yucel A, Noyan V. et al. Plasma lipocalin-2 levels in pregnancy. Acta Obstet Gynecol Scand 2012; 91: 112-116
- 15 D’Anna R, Baviera G, Corrado F. et al. First trimester serum neutrophil gelatinase-associated lipocalin in gestational diabetes. Diabet Med 2009; 26: 1293-1295
- 16 Ravnsborg T, Andersen LLT, Trabjerg ND. et al. First-trimester multimarker prediction of gestational diabetes mellitus using targeted mass spectrometry. Diabetologia 2016; 59: 970-979
- 17 Saucedo R, Valencia J, Moreno-Gonzalez LE. et al. Maternal serum adipokines and inflammatory markers at late gestation and newborn weight in mothers with and without gestational diabetes mellitus. Ginekol Polska 2021;
- 18 Komici K, Dello Iacono A, De Luca A. et al. Adiponectin and sarcopenia: a systematic review with meta-analysis. Front Endocrinol (Lausanne) 2021; 12: 576619
- 19 Shi J, Luo D, Weng H. et al. Optimally estimating the sample standard deviation from the five-number summary. Res Synth Meth 2020; 11: 641-654
- 20 Luo D, Wan X, Liu J. et al. Optimally estimating the sample mean from the sample size, median, mid-range, and/or mid-quartile range. Stat Methods Med Res 2018; 27: 1785-1805
- 21
Wan X,
Wang W,
Liu J.
et al. Estimating the sample mean and standard deviation from the sample size, median,
range and/or interquartile range. BMC Med Res Methodol 2014; 14: 135
MissingFormLabel
- 22 Lo CK, Mertz D, Loeb M. Newcastle-Ottawa Scale: comparing reviewers’ to authors’ assessments. BMC Med Res Methodol 2014; 14: 45
- 23 Ma Q, Chen Y. Study on the expression of serum level of NGAL and its relationship with gestational diabetes in early pregnancy. J Clin Exp Med (Chinese) 2015; 930-933
- 24 Mierzynski R, Poniedzialek-Czajkowska E, Dluski D. et al. The potential role of chemerin, lipocalin 2, and apelin in the diagnosis and pathophysiology of gestational diabetes mellitus. J Diabetes Res 2021; 5547228
- 25 Duan D, Niu J, Zhu B. et al. Serum level of neutrophii gelatinase-assoeiated lipocalin in preeclampsia with gestatiunal diabetes mellitus. Chin J Perinat Med (Chinese) 2012; 15: 222-227
- 26 Guo J. Relationship between neutrophil gelatinase-associated lipocalin and insulin resistance in diabetic gravida. Modern Prevent Med (Chinese) 2014; 41: 1599-1601 1604
- 27 Guo L, Zhang C, Guo Y. Changes and significance of serum LCN-2 and AOPP levels in patients with gestational diabetes mellitus complicated with preeclampsia. Shandong Med J (Chinese) 2019; 59: 12-15
- 28 Kang Y. The value of adiponectin, resistin and lipocalin-2 tests in early diagnosis of gestational diabetes mellitus. Label Immun. Clin Med (Chinese) 2018; 25: 1192-1195
- 29 Wang F, Ye L, Yang L. et al. Changes of serum neutrophic gelatinase-associated lipocalin in gestational diabetes mellitus. Chin J Microcirculat (Chinese) 2013; 23: 19-21
- 30 He X, Gu D, Chen S. et al. Clinical significanle of NGAL in women with gestational diabetes mellitus. China Med Pharm (Chinese) 2018; 8: 35-38
- 31 Plows JF, Stanley JL, Baker PN. et al. The pathophysiology of gestational diabetes mellitus. Int J Mol Sci 2018; 19: 3342
- 32 Zhang C, Liu S, Solomon CG. et al. Dietary fiber intake, dietary glycemic load, and the risk for gestational diabetes mellitus. Diabetes Care 2006; 29: 2223-2230
- 33 Binder AM, LaRocca J, Lesseur C. et al. Epigenome-wide and transcriptome-wide analyses reveal gestational diabetes is associated with alterations in the human leukocyte antigen complex. Clin Epigenet 2015; 7: 79
- 34 De la Chesnaye E, Manuel-Apolinar L, Oviedo-de Anda N. et al. [Gender differences in lipocalin 2 plasmatic levels are correlated with age and the triglyceride/high-density lipoprotein ratio in healthy individuals]. Gac Med Mex 2016; 152: 612-617
- 35 Wu G, Li H, Zhou M. et al. Mechanism and clinical evidence of lipocalin-2 and adipocyte fatty acid-binding protein linking obesity and atherosclerosis. Diabetes Metab Res Rev 2014; 30: 447-456
- 36 Abella V, Scotece M, Conde J. et al. The potential of lipocalin-2/NGAL as biomarker for inflammatory and metabolic diseases. Biomarkers 2015; 20: 565-571
- 37 Wang Y, Lam KS, Kraegen EW. et al. Lipocalin-2 is an inflammatory marker closely associated with obesity, insulin resistance, and hyperglycemia in humans. Clin Chem 2007; 53: 34-41
- 38 Yan QW, Yang Q, Mody N. et al. The adipokine lipocalin 2 is regulated by obesity and promotes insulin resistance. Diabetes 2007; 56: 2533-2540
- 39 Sun WX, Lou K, Chen LJ. et al. Lipocalin-2: a role in hepatic gluconeogenesis via AMP-activated protein kinase (AMPK). J Endocrinol Invest 2021; 44: 1753-1765
- 40 Law IK, Xu A, Lam KS. et al. Lipocalin-2 deficiency attenuates insulin resistance associated with aging and obesity. Diabetes 2010; 59: 872-882
- 41 Chan YK, Sung HK, Jahng JW. et al. Lipocalin-2 inhibits autophagy and induces insulin resistance in H9c2 cells. Mol Cell Endocrinol 2016; 430: 68-76
- 42 Chella Krishnan K, Sabir S, Shum M. et al. Sex-specific metabolic functions of adipose lipocalin-2. Mol Metab 2019; 30: 30-47
- 43 Jaberi SA, Cohen A, D’Souza C. et al. Lipocalin-2: structure, function, distribution and role in metabolic disorders. Biomed Pharmacother 2021; 142: 112002
- 44 Kamble PG, Pereira MJ, Sidibeh CO. et al. Lipocalin 2 produces insulin resistance and can be upregulated by glucocorticoids in human adipose tissue. Mol Cell Endocrinol 2016; 427: 124-132
- 45 Auguet T, Quintero Y, Terra X. et al. Upregulation of lipocalin 2 in adipose tissues of severely obese women: positive relationship with proinflammatory cytokines. Obesity (Silver Spring) 2011; 19: 2295-2300
- 46 Catalán V, Gómez-Ambrosi J, Rodríguez A. et al. Increased adipose tissue expression of lipocalin-2 in obesity is related to inflammation and matrix metalloproteinase-2 and metalloproteinase-9 activities in humans. J Mol Med (Berl) 2009; 87: 803-813
- 47 Liu JT, Song E, Xu A. et al. Lipocalin-2 deficiency prevents endothelial dysfunction associated with dietary obesity: role of cytochrome P450 2C inhibition. Br J Pharmacol 2012; 165: 520-531
- 48 Li D, Yan Sun W, Fu B. et al. Lipocalin-2 – the myth of its expression and function. Basic Clin Pharmacol Toxicol 2020; 127: 142-151
- 49 Clerico A, Galli C, Fortunato A. et al. Neutrophil gelatinase-associated lipocalin (NGAL) as biomarker of acute kidney injury: a review of the laboratory characteristics and clinical evidences. Clin Chem Lab Med 2012; 50: 1505-1517
- 50 Valsamakis G, Kumar S, Creatsas G. et al. The effects of adipose tissue and adipocytokines in human pregnancy. Ann N Y Acad Sci 2010; 1205: 76-81
- 51 Deis JA, Guo H, Wu Y. et al. Adipose lipocalin 2 overexpression protects against age-related decline in thermogenic function of adipose tissue and metabolic deterioration. Mol Metab 2019; 24: 18-29
- 52 Tan BK, Adya R, Shan X. et al. Ex vivo and in vivo regulation of lipocalin-2, a novel adipokine, by insulin. Diabetes Care 2009; 32: 129-131
- 53 Moreno-Navarrete JM, Manco M, Ibáñez J. et al. Metabolic endotoxemia and saturated fat contribute to circulating NGAL concentrations in subjects with insulin resistance. Int J Obes (Lond) 2010; 34: 240-249
- 54
Stroup DF,
Berlin JA,
Morton SC.
et al. Meta-analysis of observational studies in epidemiology: a proposal for
reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE)
group. JAMA 2000; 283: 2008-2012
MissingFormLabel